Press Releases

Keyword Search

News Category Financial

Year None2026202520242023202220212020201920182017201620152014

Date	Title
06/30/26	MediciNova CEO Provides Shareholder Update
06/08/26	MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment
05/26/26	MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
04/27/26	New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation
03/16/26	MediciNova to Participate at the 38th Annual ROTH Conference
01/29/26	MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
01/06/26	2026 New Year’s Greetings from the CEO